Patent law tightens: fewer ways to challenge weak patents in court

What it does

The PREVAIL Act amends U.S. patent law to strengthen patent protections and restrict challenges to patent validity. It requires the Patent Trial and Appeal Board (PTAB) to use 3-member panels, establishes a code of conduct for PTAB judges, and significantly limits repetitive patent challenges by blocking petitioners from filing multiple validity challenges in different forums (courts, International Trade Commission, or PTAB) once one proceeding is underway. It also tightens rules on who can challenge patents (requiring disclosure of financial backers as 'real parties in interest'), prevents certain repeat challenges, and eliminates USPTO fee diversion by creating a dedicated patent fee fund. The bill aims to reduce what it characterizes as harassment through repetitive patent challenges while strengthening inventor property rights.

Why we flagged it

The bill's core mechanism is procedural: it restructures PTAB operations (3-member panels, conduct codes, timing rules) and restricts the forums and timing for patent validity challenges. While framed as protecting inventors, the operative effect is to consolidate patent challenges into a single proceeding and raise barriers to challenging patents across multiple venues.

What the text implies

• The 'single forum' and 'estoppel' provisions (Sections 4 & 5) may effectively bar small competitors and nonprofits from challenging weak patents in federal court once a PTAB proceeding is initiated, even if the PTAB proceeding fails—shifting leverage toward patent holders.
• The 'real party in interest' disclosure requirement may chill funding of patent challenges by nonprofits, universities, and public-interest organizations that rely on anonymous or pooled funding, as they must now disclose all financial backers.
• The presumption of validity and 'clear and convincing evidence' standard for petitioners (vs. preponderance for substitute claims) makes it harder to invalidate issued patents, potentially protecting low-quality patents from challenge.
• Elimination of USPTO fee diversion creates a dedicated patent fund, but the bill does not mandate how those fees are spent—the Director retains discretion, potentially allowing fee revenue to be used for activities beyond patent processing.
• The 45-day and 90-day decision deadlines for rehearing may compress judicial review and reduce the quality of PTAB decisions if the Board cannot meet timelines without cutting corners.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill offers genuine public benefits—stronger procedural safeguards for patent owners (3-judge panels, transparency on who funds challenges, reduced harassment through repetitive filings) and dedicated USPTO funding improve patent system integrity. However, it simultaneously restricts citizens' and small competitors' ability to challenge potentially invalid patents through multiple legal avenues, raising the cost and complexity of challenging weak patents and potentially entrenching monopolie

Who stands to gain

• patent holders (especially large corporations with patent portfolios)
• patent prosecution firms and patent counsel
• entities holding large patent portfolios

Named in the bill

Patent Trial and Appeal Board (PTAB), U.S. Patent and Trademark Office (USPTO), Director of USPTO, International Trade Commission (ITC), Small Business Administration, institutions of higher education, nonprofit organizations (501(c)(3))

Where it stands

3 cosponsors: 2 Democrats, 1 Republicans.

• May 1, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• May 1, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

39 lobbying clients named this bill on 53 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $44,788,909 in lobbying spend. A filing names 13 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 99% of bills with at least one filing.

Christopher Coons, the sponsor, reported $1,402,800 in PAC receipts in the 2026 cycle. $8,500 of that came from 3 PACs tied to these lobbying clients.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Amazon.com Services LLC — $4,360,000 on 1 filing
• Apple Inc — $2,740,000 on 1 filing
• Microsoft Corporation — $2,690,000 on 1 filing
• Amgen Inc — $2,440,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.